Innovest Global Completes Sale of StemVax Therapeutics to NovAccess Global

Author's Avatar
Sep 10, 2020
Article's Main Image

Innovest Global Receives 7.5 Million Shares of NovAccess Global Common Stock as Consideration for StemVax Therapeutics; Divestiture of Biotech Subsidiary Signals Renewed Focus on Growing Industrials Business